Abbott raises 2026 profit forecast on strength in diagnostics, heart devices
1 min read
The coverage · 2 reports
- Investing.comFirst reportAbbott raises 2026 profit forecast on strength in diagnostics, heart devices ↗
- Yahoo FinanceLatest
The story
Abbott raised its 2026 profit forecast as demand in diagnostics and heart devices strengthened. The headline does not provide the size of the increase or updated earnings figures, so the magnitude of the guidance change remains unclear.
The upgrade reinforces the two businesses as the main operating drivers for ABT. Abbott generated $44.3 billion of revenue in fiscal 2025, up 5.7% year over year, with a 14.7% net margin and diluted EPS of $3.72.
The bull case is that stronger diagnostics and cardiovascular-device performance can lift earnings above the prior plan and extend the company’s established growth trajectory. The bear case is that the market may already reflect much of Abbott’s execution, while the missing details on the forecast increase make it difficult to assess the durability of the improvement.
The next focus is the size and composition of the revised 2026 forecast, including whether the benefit is broad-based or concentrated in these two segments. Investors will also parse subsequent results for confirmation that revenue growth is translating into sustained margin and EPS improvement.
The case — both sides
A higher 2026 profit forecast combined with 5.7% reported revenue growth suggests diagnostics and heart devices may be extending Abbott’s earnings trajectory beyond the prior plan.
The size of the upgrade is undisclosed and ABT’s 14.7% net margin leaves limited evidence here that incremental segment strength will create a sufficiently large earnings surprise to offset expectations.
The house read
Two-sidedABT’s raised 2026 profit outlook puts the durability of diagnostics and heart-device growth—and the valuation already assigned to it—in focus.
Wrong ifThe setup weakens if the forecast increase is modest, concentrated in one segment, or fails to produce sustained EPS and margin improvement in the next reported results.
Published read · research, not advice